{"id":38998,"date":"2017-08-05T07:13:58","date_gmt":"2017-08-05T07:13:58","guid":{"rendered":"https:\/\/www.biphoo.com\/bipnews\/?p=38998"},"modified":"2017-08-05T07:20:02","modified_gmt":"2017-08-05T07:20:02","slug":"acute-migraine-drug-succeeds-late-stage-study","status":"publish","type":"post","link":"https:\/\/www.biphoo.com\/bipnews\/health\/medical\/acute-migraine-drug-succeeds-late-stage-study.html","title":{"rendered":"Acute migraine drug succeeds in late-stage study"},"content":{"rendered":"<h2 style=\"text-align: justify\"><span style=\"font-size: 18pt;color: #000000\"><strong><span style=\"font-family: Arial, Helvetica, sans-serif\">Acute migraine drug succeeds in late-stage study<\/span><\/strong><\/span><\/h2>\n<p style=\"text-align: justify\"><span style=\"font-family: Arial, Helvetica, sans-serif;font-size: 14pt;color: #000000\">Acute migraine drug succeeds in late-stage study:- Eli Lilly and Co said on Friday said its acute migraine drug, lasmiditan, induced a statistically significant improvement in pain relief against a placebo in a late-stage study.<\/span><\/p>\n<p style=\"text-align: justify\"><span style=\"font-family: Arial, Helvetica, sans-serif;font-size: 14pt;color: #000000\">The trial tested three doses of the oral drug against a placebo. Patients in the trial had an average of more than five migraine attacks per month.<\/span><\/p>\n<p style=\"text-align: justify\"><span style=\"font-family: Arial, Helvetica, sans-serif;font-size: 14pt;color: #000000\">Lilly, which acquired lasmiditan through its $960 million purchase of CoLucid Pharmaceuticals in January, said it plans to file a U.S. marketing application for the drug in the second half of 2018.<\/span><\/p>\n<p style=\"text-align: justify\"><span style=\"font-family: Arial, Helvetica, sans-serif;font-size: 14pt;color: #000000\">About 40 million Americans suffer from migraines, and the disease costs the United States about $36 billion annually in healthcare and lost productivity, according to the Migraine Research Foundation.<\/span><\/p>\n<p style=\"text-align: justify\"><span style=\"font-family: Arial, Helvetica, sans-serif;font-size: 8pt;color: #000000\">source: http:\/\/www.foxnews.com\/health\/2017\/08\/04\/acute-migraine-drug-succeeds-in-late-stage-study.html<\/span><\/p>\n<div class=\"fb-background-color\">\n\t\t\t  <div \n\t\t\t  \tclass = \"fb-comments\" \n\t\t\t  \tdata-href = \"https:\/\/www.biphoo.com\/bipnews\/health\/medical\/acute-migraine-drug-succeeds-late-stage-study.html\"\n\t\t\t  \tdata-numposts = \"10\"\n\t\t\t  \tdata-lazy = \"true\"\n\t\t\t\tdata-colorscheme = \"light\"\n\t\t\t\tdata-order-by = \"social\"\n\t\t\t\tdata-mobile=true>\n\t\t\t  <\/div><\/div>\n\t\t  <style>\n\t\t    .fb-background-color {\n\t\t\t\tbackground: #ffffff !important;\n\t\t\t}\n\t\t\t.fb_iframe_widget_fluid_desktop iframe {\n\t\t\t    width: 630px !important;\n\t\t\t}\n\t\t  <\/style>\n\t\t  ","protected":false},"excerpt":{"rendered":"<p>Acute migraine drug succeeds in late-stage study Acute migraine drug succeeds in late-stage study:- Eli Lilly and Co said on Friday said its acute migraine drug, lasmiditan, induced a statistically significant improvement in pain relief against a placebo in a late-stage study. The trial tested three doses of the oral [&hellip;]<\/p>\n","protected":false},"author":13,"featured_media":39009,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[951],"tags":[37071],"class_list":["post-38998","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-medical","tag-acute-migraine-drug-succeeds-in-late-stage-study"],"_links":{"self":[{"href":"https:\/\/www.biphoo.com\/bipnews\/wp-json\/wp\/v2\/posts\/38998","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.biphoo.com\/bipnews\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.biphoo.com\/bipnews\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.biphoo.com\/bipnews\/wp-json\/wp\/v2\/users\/13"}],"replies":[{"embeddable":true,"href":"https:\/\/www.biphoo.com\/bipnews\/wp-json\/wp\/v2\/comments?post=38998"}],"version-history":[{"count":0,"href":"https:\/\/www.biphoo.com\/bipnews\/wp-json\/wp\/v2\/posts\/38998\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.biphoo.com\/bipnews\/wp-json\/wp\/v2\/media\/39009"}],"wp:attachment":[{"href":"https:\/\/www.biphoo.com\/bipnews\/wp-json\/wp\/v2\/media?parent=38998"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.biphoo.com\/bipnews\/wp-json\/wp\/v2\/categories?post=38998"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.biphoo.com\/bipnews\/wp-json\/wp\/v2\/tags?post=38998"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}